- AU$13.82m
- AU$13.07m
- AU$2.20m
- 32
- 25
- 20
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.05 | ||
| Price to Tang. Book | 9.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.01% | ||
| Return on Equity | -74.8% | ||
| Operating Margin | -92.08% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1.01 | 1.98 | 1.82 | 1.59 | 2.2 | n/a | n/a | 82.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises medication-assisted treatment programs and biopharmaceuticals, specifically methylenedioxy-methylamphetamine (MDMA) analogues and Ultra-Pure cannabidiol (CBD) capsules. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.
Directors
- Stewart Washer CHM
- Su-Mei Sain CFO
- Michael Winlo MDR
- Karen Smith EDR (53)
- Alistair Vickery EDR
- Matthew Callahan NED
- Sir John Tooke NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 19th, 2018
- Public Since
- February 12th, 2020
- No. of Shareholders
- 3,351
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 460,589,396
- Address
- D2 661 Newcastle Street, LEEDERVILLE, 6007
- Web
- https://www.emeraldclinics.com.au/
- Phone
- +61 865592800
- Auditors
- Stantons International Audit and Consulting PTY Ltd
Upcoming Events for EMD
Similar to EMD
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Emyria share price?
As of Today at 20:27 UTC, shares in Emyria are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the Emyria share price performed this year?
Shares in Emyria last closed at AU$0.03 and the price had moved by -49.15% over the past 365 days. In terms of relative price strength the Emyria share price has underperformed the ASX All Ordinaries Index by -49.91% over the past year.
What are the analyst and broker recommendations for Emyria?
There is no consensus recommendation for this security.
Find out moreWhat is the Emyria dividend yield?
Emyria does not currently pay a dividend.
Does Emyria pay a dividend?
Emyria does not currently pay a dividend.
When does Emyria next pay dividends?
Emyria does not currently pay a dividend.
How do I buy Emyria shares?
To buy shares in Emyria you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Emyria?
As of the previous close price of AU$0.03, shares in Emyria had a market capitalisation of AU$13.82m.
Where are Emyria shares listed?
Here are the trading details for Emyria:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: EMD
What kind of share is Emyria?
Based on an overall assessment of its quality, value and momentum Emyria is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Emyria share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Emyria share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Emyria. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -0.94%.
As of the last closing price of AU$0.03, shares in Emyria were trading -16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Emyria PE Ratio?
The Emyria PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Emyria?
Emyria's management team is headed by:
- Stewart Washer - CHM
- Su-Mei Sain - CFO
- Michael Winlo - MDR
- Karen Smith - EDR
- Alistair Vickery - EDR
- Matthew Callahan - NED
- Sir John Tooke - NED